| avelumab based treatment | nivolumab based treatment | pembrolizumab based treatment |
| avelumab alone | nivolumab alone | pembrolizumab alone |
| mGC or mGEJC - 2nd Line (L2) | | | |
| mGC or mGEJC - L2 - all population 4 | | | |
| mGC or mGEJC - L2 - PDL1 positive 1 | | | |
Comparator:
vs Standard of Care (SoC); vs placebo; vs paclitaxel;
Risk of bias:
low;
some concerns;
high;
NA;